论文部分内容阅读
目的探讨肝动脉插管化疗栓塞(TACE)联合CIK细胞免疫疗法预防肝癌切除术后复发的影响。方法 140例接受肝癌根治性切除术的患者,根据术后2个月内是否行预防性TACE及CIK治疗分为三组:术后行预防性TACE术联合CIK免疫治疗者57例为联合预防组;术后行预防性TACE术者41例为TACE预防组;仅行支持对症治疗者42例为对照组。对比分析三组患者术后1、2、3年的累积复发率及术后复发的独立危险因素。结果联合预防组1、2、3年的累积复发率为39.9%、49.2%和57.3%;TACE预防组1、2、3年的累积复发率为43.5%、68.5%和81.5%;对照组1、2、3年的累积复发率为51.2%、61.3%和68.3%。联合预防组与TACE预防组比较,差异有统计学意义(P=0.040),联合预防组与对照组比较,差异有统计学意义(P=0.046),单纯TACE预防组与对照组比较,差异无统计学意义(P=0.800)。肿瘤个数是术后复发的独立危险因素。结论术后补充TACE术联合CIK细胞免疫治疗是降低患者复发率的有效手段,对于多发肿瘤尤为显著。
Objective To investigate the effect of transcatheter arterial chemoembolization (TACE) combined with CIK cell immunotherapy on the prevention of recurrence after liver cancer resection. Methods One hundred and forty patients undergoing radical resection of hepatocellular carcinoma were divided into three groups according to whether prophylactic TACE and CIK were administered within 2 months: Fifty-seven patients were treated with prophylactic TACE combined with CIK immunotherapy. ; 41 patients who underwent prophylactic TACE were TACE prophylaxis group; 42 patients who only supported symptomatic treatment were control group. The cumulative recurrence rates at 1, 2 and 3 years after operation and the independent risk factors for postoperative recurrence were compared between the three groups. Results The cumulative recurrence rates were 39.9%, 49.2% and 57.3% in the combined prophylaxis group at 1, 2 and 3 years respectively; the cumulative recurrence rates at 1, 2 and 3 years in the TACE prophylaxis group were 43.5%, 68.5% and 81.5% The cumulative recurrence rates in 2 and 3 years were 51.2%, 61.3% and 68.3% respectively. Compared with TACE prevention group, the difference was statistically significant (P = 0.040), there was significant difference between the combination prevention group and the control group (P = 0.046), the difference between the TACE prevention group and the control group was no significant difference Statistical significance (P = 0.800). The number of tumors is an independent risk factor for postoperative recurrence. Conclusion Postoperative TACE combined with CIK cell immunotherapy is an effective way to reduce the recurrence rate of patients, especially for multiple tumors.